Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT premeeting toward consensus on core sets for randomized controlled trials

Maria Antonietta D'Agostino, Kathleen M. Andersen, Jonathan T.L. Cheah, Lyn March, Susan J. Bartlett, Dorcas Beaton, Clifton O. Bingham, Peter M. Brooks, Robin Christensen, Philip G. Conaghan, Maria-Antonietta D’Agostino, Maarten De Wit, Amylou C. Dueck, Susan M. Goodman, Shawna Grosskleg, Catherine L. Hill, Martin Howell, Sarah L. Mackie, Bethan Richards, Beverly SheaJasvinder A. Singh, Vibeke Strand, Peter Tugwell, George A. Wells, Lee S. Simon

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

Objective. Outcome Measures in Rheumatology (OMERACT) convened a premeeting in 2018 to bring together patients, regulators, researchers, clinicians, and consumers to build upon previous OMERACT drug safety work, with patients fully engaged throughout all phases. Methods. Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings. Results. Five themes pertaining to drug safety measurement emerged. Conclusion. Current approaches have failed to include data from the patient’s perspective. A better understanding of how individuals with rheumatic diseases view potential benefits and harms of therapies is essential.
Lingua originaleEnglish
pagine (da-a)1053-1058
Numero di pagine6
RivistaTHE JOURNAL OF RHEUMATOLOGY
Volume46
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • Antirheumatic Agents
  • Clinical trials disease-modifying antirheumatic drugs
  • Humans
  • OMERACT
  • Patient Satisfaction
  • Patient satisfaction
  • Randomized Controlled Trials as Topic
  • Rheumatic Diseases
  • Risk Assessment
  • Risk assessment
  • Treatment Outcome

Fingerprint Entra nei temi di ricerca di 'Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT premeeting toward consensus on core sets for randomized controlled trials'. Insieme formano una fingerprint unica.

Cita questo